Abstract
Matrix metalloproteinases (MMPs) are a family of zinc-containing enzymes involved in the degradation and remodeling of extracellular matrix proteins. The activities of these enzymes are well regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). Chronic stimulation of MMP activities due to an imbalance in the levels of MMPs and TIMPs has been implicated in the pathogenesis of a variety of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. Thus, MMP inhibitors are expected to be useful for the treatment of these disorders. This article reviews briefly the biochemistry of MMPs and evidence for their pathogenic roles using molecular biology approaches. Biomolecular structures used in the design of MMP inhibitors are thoroughly covered. Major emphasis is on recently published potent, small molecular weight MMP inhibitors and their pharmacological properties. Finally, available clinical results of compounds in development are summarized.
Keywords: Metalloproteinase inhibitors, angiogenesis, tumor induced, hydroxamate moiety, non peptidic sulfonamide, uninhibited catalytic domain, gelatinase, murine model, spiro cyclopentyl, Biaryl oxime
Current Medicinal Chemistry
Title: The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors
Volume: 8 Issue: 4
Author(s): Jerry W. Skiles, Nina C. Gonnella and Arco Y. Jeng
Affiliation:
Keywords: Metalloproteinase inhibitors, angiogenesis, tumor induced, hydroxamate moiety, non peptidic sulfonamide, uninhibited catalytic domain, gelatinase, murine model, spiro cyclopentyl, Biaryl oxime
Abstract: Matrix metalloproteinases (MMPs) are a family of zinc-containing enzymes involved in the degradation and remodeling of extracellular matrix proteins. The activities of these enzymes are well regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). Chronic stimulation of MMP activities due to an imbalance in the levels of MMPs and TIMPs has been implicated in the pathogenesis of a variety of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. Thus, MMP inhibitors are expected to be useful for the treatment of these disorders. This article reviews briefly the biochemistry of MMPs and evidence for their pathogenic roles using molecular biology approaches. Biomolecular structures used in the design of MMP inhibitors are thoroughly covered. Major emphasis is on recently published potent, small molecular weight MMP inhibitors and their pharmacological properties. Finally, available clinical results of compounds in development are summarized.
Export Options
About this article
Cite this article as:
Skiles W. Jerry, Gonnella C. Nina and Jeng Y. Arco, The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors, Current Medicinal Chemistry 2001; 8 (4) . https://dx.doi.org/10.2174/0929867013373417
DOI https://dx.doi.org/10.2174/0929867013373417 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway
Current Neuropharmacology RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Allergy and Inflammation: An Immunological and Therapeutic Approach
Recent Patents on Inflammation & Allergy Drug Discovery Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Ezetimibe and Vascular Inflammation
Current Vascular Pharmacology Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19
Current Pharmaceutical Design APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Biological Markers for Multiple Sclerosis
Current Medicinal Chemistry A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Inflammation, High Density Lipoprotein and Endothelium
Current Medicinal Chemistry Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Synthesis and Biological Activity of Prostaglandin Analogs Containing Heteroatoms in the Cyclopentane Ring
Current Organic Chemistry Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs)
Recent Patents on Anti-Cancer Drug Discovery Applications of Machine Learning in miRNA Discovery and Target Prediction
Current Genomics